Percentage of patients with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit: aged 13 years and older who have a history of a CD4 count less than or equal to 500 cells/mm3; aged 13 years and older who have a history of an AIDS-defining illness, regardless of CD4 count; or who are pregnant, regardless of CD4 count or age, who were prescribed potent antiretroviral therapy
- Measure TypeElectronic Clinical Quality Measure (eCQM)Level Of AnalysisCare SettingNumerator
Patients who were prescribed potent antiretroviral* therapy
*Potent antiretroviral therapy is described as any antiretroviral therapy that has demonstrated optimal efficacy and results in durable suppression of HIV as shown by prior clinical trialsDenominatorA. All patients aged 13 years and older with a diagnosis of HIV/AIDS, with at least two medical visits during the measurement year, with at least 90 days between each visit, who have a history of a CD4 count less than or equal to 500 cells/mm3; and
B. All patients aged 13 years and older with a diagnosis of HIV/AIDS, with at least two medical visits during the measurement year, with at least 90 days between each visit, who have a history an AIDS-defining illness**, regardless of CD4 count; and
C. All patients with a diagnosis of HIV/AIDS, with at least two medical visits during the measurement year, with at least 90 days between each visit, who are pregnant, regardless of CD4 count or age.
**The most commonly used case definition for AIDS is the 1993 Revised Surveillance Case Definition from the CDC. It includes: Candidiasis of bronchi, trachea, or lungs; candidiasis, esophageal; cervical cancer, invasive; coccidiodomycosis, disseminated or extrapulmonary; cryptococcosis, extrapulmonary; crytosporidiosis, chronic intestinal (greater than 1 month’s duration); cytomegalovirus disease (other than liver, spleen, or nodes); cytomegalovirus retinitis (with loss of vision); encephalopathy, HIV-related; herpes simplex: chronic ulcer(s) (greater than 1 month’s duration); or bronchitis, pneumonitis, or esophagitis; histoplasmosis, disseminated or extrapulmonary; isosporiasis, chronic intestinal (greater than 1 month’s duration); Kaposi’s sarcoma; lymphoma, Burkitt’s (or equivalent term); lymphoma, immunoblastic (or equivalent term); lymphoma, primary, of brain; mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary; mycobacterium tuberculosis, any site (pulmonary or extrapulmonary); mycobacterium, other species or unidentified species, disseminated or extrapulmonary; pneumocystis carinii pneumonia; pneumonia, recurrent; progressive multifocal leukoencephalopathy; salmonella septicemia, recurrent; toxoplasmosis of brain; wasting syndrome due to HIV. (Aberg, 2009; National Center for Infectious Diseases Division of HIV/AIDS)
Definition of “Medical Visit” - any visit with a health care professional who provides routine primary care for the patient with HIV/AIDS (may be but is not limited to a primary care clinician, ob/gyn, pediatrician, infectious diseases specialist)
Note: For potent antiretroviral therapy recommendations refer to current DHHS guidelines available at www.aids.gov
Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, Oleske JM, Currier JS, Gallant JE; HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009 Sep 1;49(5):651-81. Available at http://www.uphs.upenn.edu/bugdrug/antibiotic_manual/idsahivprimarycare2009.pdf. Accessed May 25, 2012.
National Center for Infectious Diseases Division of HIV/AIDS. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMRW Recomm Rep. 1992;41(RR-17):1-19.ExclusionsNone
Testing Data Sources
- Measure StructureClinical Condition Topic AreaTarget PopulationNational Quality Strategy PrioritiesHealth and Well-Being
- Risk Adjustment
- Current or planned use(s)
- Most Recent Endorsement ActivityMeasure Retired and Endorsement Removed Infectious Disease Endorsement Maintenance ProjectInitial EndorsementEndorsement StatusLast UpdatedRemoval Date
- Steward Organization EmailSteward Organization Copyright
This Measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposed, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, (on behalf of the Consortium) or NCQA. Neither the AMA, NCQA, Consortium nor its members shall be responsible for any use of the Measure.
© 2012 American Medical Association and National Committee for Quality Assurance. All Rights Reserved
Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.